Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
Date:4/29/2008

- First 15 Patients Are Enrolled and Dosing With Bavituximab Plus Docetaxel

Combination Regimen is Underway -

TUSTIN, Calif., April 29 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that it has completed enrollment in the first stage of its Phase II trial of bavituximab in combination with chemotherapy in patients with advanced breast cancer. The main objective of the safety and efficacy study is to assess the overall response rate to the combination of bavituximab with docetaxel, a chemotherapy drug commonly used to treat breast cancer.

"We are very pleased that patient enrollment in this trial has proceeded quickly, reflecting the enthusiasm and efficiency of our clinical colleagues in Europe and the level of patient interest in a potential new therapy for this difficult disease," said Steven W. King, president and CEO of Peregrine. "We look forward to providing an update on the trial as patients continue to be dosed in the study and tumor response data is generated."

As part of this trial's two-stage design, 15 patients with locally advanced or metastatic breast cancer have been enrolled initially. The primary objective of the multi-center, open-label study is to assess overall tumor response rate to the combination of bavituximab with docetaxel. The study may be expanded to include up to an additional 31 subjects if promising results are seen in the first 15 patients. Patients enrolled in the trial will remain in the study until disease progression.

Secondary objectives of the Phase II study include measur
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
2. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
3. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
4. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a multivariate ... has appointed Holly B. Bauzon as Vice ... Bauzon has a proven track record in both increasing ... companies. She has more than 20 years of healthcare ... the position of Director, Lab Services Sales and Managed ...
(Date:8/21/2014)... 21, 2014 The spinal column is one of ... Signals carried to and from the brain through the column ... system. Injury or ailment here can be life altering, and ... of control over their body. Though back injury and disease ... there are more options available to make things better than ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance ... comic series designed to educate children about the most common ... Medikidz Explain Epilepsy comic series tells a fictional ... navigating middle school while living with epilepsy. ... there is still so much misinformation and lack of awareness ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3
... , MINNEAPOLIS, Dec. 29 Target® announces ... seven Target Clinic locations in Maryland, while supplies last. ... will be available daily at Target Clinic locations during clinic ... cover the cost). For information on which stores ...
... , , MOUNTAIN VIEW, Calif., Dec. 29 ... developing innovative, next-generation medical therapies to address unmet needs in ... Drug Application (NDA) has been submitted to the U.S. Food ... drug for the treatment of obesity, including weight loss and ...
Cached Medicine Technology:VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 2VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 3VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 4VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 5
(Date:8/23/2014)... Albany, New York (PRWEB) August 23, 2014 ... invasive surgeries done to remove plaques, etc, thereby addressing ... surgeries restore the flow of blood to the other ... the flow of oxygenated blood. These procedures require the ... made of metal composites and polymers), these catheters are ...
(Date:8/23/2014)... PA (PRWEB) August 23, 2014 Having been ... and dental hygienist from Arlington, Texas, saw a need for ... and toothpaste. "That’s when I came up with the idea ... No-Brush provides an effective way for a user to clean ... need to carry multiple items. It also helps avoid plaque ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 A team of ... mesothelioma last longer when preceded by surgery and delivered by ... on the new study. Click here to read it ... studied the cases of mesothelioma patients who underwent ... conforming radiotherapy dose to the shape of a tumor. ...
(Date:8/23/2014)... August 23, 2014 Legal Insider ... created by Greg Marks has been generating a buzz ... month. The commotion surrounding the new product has drawn ... review. , “In recent years the market ... systems, commonly referred to as robots or ‘bots,'” reports ...
(Date:8/23/2014)... GBI Research, the leading business intelligence ... in Major Developed Markets to 2020 - New and ... which provides in-depth analysis of the critical care market ... and Canada. The report provides an estimation of market ... It covers critical care indications that are being treated ...
Breaking Medicine News(10 mins):Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3
... Southeast Florida Market, NORTH HOLLYWOOD, Calif., Aug. ... IPCM ), a leading national hospitalist,physician group practice, ... of Hospitalists of America (HOA). The acquisition,expands IPC,s ... with a network of independent physicians, who perform ...
... InteKrin Therapeutics, Inc.,a clinical stage biopharmaceutical company ... and obesity today announced it has,completed the first ... $18.25,million. The financing was led by Skyline Ventures ... Ph.D. of Skyline will join InteKrin,s Board of,Directors. ...
... (Nasdaq:,EVVV), a global endovascular device company, today announced the,appointment ... effective,immediately. Mr. Kohrs will also serve as a member ... director of ev3 from June 2005,until October 2007 at ... the completion of ev3,s acquisition of FoxHollow Technologies,Inc., ...
... the Virginia Bioinformatics Institute (VBI) at Virginia Tech have ... proteins in oomycete plant pathogens that enables the proteins ... region contains the amino acid sequence motifs RXLR and ... proteins across the membrane surrounding plant cells without any ...
... less rest linked to doubled chance of weight gain, study ... little sleep or not spending enough time in rapid eye ... and teens, a new U.S. study. , For three consecutive ... 7 to 17. They looked at total sleep time, time ...
... Study finds that older patients, concerns often go unspoken and ... ... surgery with,their orthopaedic surgeons, older patients frequently do not raise all of,their ... The Journal of Bone and Joint Surgery found that patients age,60 or ...
Cached Medicine News:Health News:IPC The Hospitalist Company Completes Acquisition of Hospitalists of America 2Health News:InteKrin Therapeutics Announces $20 Million Series C Financing 2Health News:ev3 Inc. Appoints Douglas W. Kohrs to Board of Directors 2Health News:Key to virulence protein entry into host cells discovered 2Health News:Kids Who Sleep Poorly at Risk for Being Overweight 2Health News:Video: Communication is Key to Ease Worry about Orthopaedic Surgery 2Health News:Video: Communication is Key to Ease Worry about Orthopaedic Surgery 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: